X. Bian et al. / Bioorg. Med. Chem. Lett. 16 (2006) 1380–1383
1383
9. Gribble, F. M.; Ashcroft, F. M. Metab. Clin. Exp. 2000,
49, 3.
10. Andrew, J. P.; Claire, T.; Craig Mckay, M. Bioorg. Med.
Chem. Lett. 2004, 14, 813.
11. Ashcroft, F. M.; Gribble, F. M. Diabetes 1999, 42, 903.
12. Gribble, F. M.; Tucker, S. J. Diabetes 1998, 47, 1412.
13. Mikhailov, M. V.; Mikhailov, E. A. FEBS Lett. 2000, 482,
59.
14. Mikhailov, M. V.; Ashcroft, S. J. H. J. Biol. Chem. 2000,
275, 3360.
15. Langchong, H.; Xindu, G. New Progr. Biomed. Chroma-
togr. 1996, 3, 8.
16. Langchong, H.; Guangde, Y.; Xindu, G. Chin. Sci. Bull.
1999, 44, 826.
17. Langchong, H.; Sicen, W.; Geng, X. Chromatographia
2001, 54, 77.
derived from CMC screening with protoberberinium, it
seems that the substations that exist on ring A are
important for binding activity. The binding affinity dis-
appeared when the methylenedioxy function at C-2 and
C-3 was replaced by other groups. The binding interac-
tions were affected by the station and environment of
N-7. The aromatic quaternary nitrogen may not be the
structure of berberine derivatives that is required for
hypoglycemic effects to occur. For quaternary salts,
which were produced by alkylation of tetrahydrogen
berberine, the hydrophobic force of alkyl groups may
play an important role in their binding interaction. Of
all the synthesized protoberberiniums, compound 14
was the most effective in lowering blood glucose.
18. Guangde, Y.; Langchong, H.; Xiaoli, B. Chin. Sci. Bull.
2005, 50, 1709.
19. Liu, D.; Yang, L. X.; Cui, S.-L. China J. Chin. Mater.
Med. 1997, 22, 79.
20. Iwasa, K.; Hye-Sook, K.; Yusuke, W. Eur. J. Med. Chem.
1998, 33, 65.
Acknowledgment
This work was supported by the Natural Science
Foundation of Shaanxi Province (No. 2003C205).
21. Jie, Z.; Liqin, W. Chinese J. Intergrative Med. Cardio/
Cerebrovasc. Dis. 2003, 1, 160.
22. Iwasa, K.; Nanba, H.; Lee, D.-U. Planta Med. 1998, 64,
748.
References and notes
1. DeFronzo, R. A.; Bonadonna, R. C.; Ferrannini, E.
Diabetes Care 1992, 15, 318.
23. Iwasa, K.; Kam imauchi, M.; Ueki, M. Eur. J. Med.
Chem. 1996, 31, 469.
2. Kahn, S. E.; Porte, D. J. Diabetes Mellitus 1996, 45, 487.
3. Ruderman, N. B.; Schneider, S. H. Diabetes Care 1992, 15,
1784.
4. Satyanarayana, M.; Priti, T.; Brajendra, K. Bioorg. Med.
Chem. 2004, 12, 883.
5. Bennett, P. H. Diabet. Metab. Rev. 1997, 13, 583.
6. Ward, W. K.; Beard, J. C.; Halter, J. B.; Pfeifer, M. A.;
Porte, D. J. R., Jr. Diabetes Care 1984, 7, 491.
7. Bailey, C. J. Proc. Nutr. Soc. 1991, 50, 619.
8. Steven, E.; Kahn, M. B. Am. J. Med. 2000, 108, 2s.
24. Iwasa, K.; Kam imauchi, M. Planta Med. 1997, 63, 196.
25. Shuyun, X.; Rulian B.; Xiu C. In Method of Pharmaco-
logical Experiment. The PeopleÕs Medical Publishing
House, Beijing, 2002; pp 1037.
26. Note: the chromatographic conditions in the CMC model:
rabbit pancreatic-islet b-cell membrane column
(50 mm · 2.0 mm i.d.) was used. The mobile phase was
25 mM ammonium sulfate buffer (pH 7.4), with a flow rate
of 0.5 mL/min. The detection wavelength was 262 nm, at a
column temperature of 37 0.5 ꢁC.